SUBSCRIBE
SUBSCRIBE
News   Policy

Biotechnology Industry Organization (BIO) Urges Senate Committee on Finance Not to Limit Patients’ Access to Therapies

April 13, 2007 | 
1 min read
WASHINGTON--(BUSINESS WIRE)--The Biotechnology Industry Organization (BIO) opposes the Chairman’s Mark to the Medicare Prescription Drug Price Negotiation Act of 2007 (S. 3) which is being considered by the Senate Committee on Finance today.
Regulatory
MORE ON THIS TOPIC
Government
American Medical Association Urges RFK Jr. to Maintain Preventive Task Force
July 28, 2025
 · 
2 min read
 · 
Tristan Manalac
Confused businessman stands in front of different arrows . The concept of hard choices.
Regulatory
Drug Pricing Just One Point of Confusion Over New FDA Vouchers
July 28, 2025
 · 
4 min read
 · 
Dan Samorodnitsky
Poster sketch image artwork photo collage of body language finger showing gesture symbol thumb down dislike dissatisfied minus no opinion.
Regulatory
Sarepta Fallout Continues With EU’s Negative Opinion of Elevidys in Ambulatory Patients
July 25, 2025
 · 
2 min read
 · 
Tristan Manalac
Problems and Challenges. Businessman stands on question mark
Gene therapy
Sarepta’s Future Increasingly Uncertain as FDA Eyes New Study for Elevidys
July 25, 2025
 · 
4 min read
 · 
Tristan Manalac